METHODS, COMPOSITIONS, AND DEVICES FOR SUPPLYING DIETARY FATTY ACID NEEDS
Nutritional formulas comprising long-chain polyunsaturated fatty acids (LC-PUFAs) are provided, along with methods and devices for preparing and/or administering nutritional formulas. In some embodiments, a percentage of the LC-PUFAs in the nutritional formula are in the form of monogiycerides and/or free fatty acids. In some embodiments, the nutritional formulas do not comprise added lipase. Also provided are methods for providing nutrition to a subject, methods for improving fat absorption, methods for improving cognitive ability, methods for preventing chronic lung disease, and methods for reducing the length of time a patient requires total parenteral nutrition.
1 .- 20 . (canceled)
21 . A method of providing a nutritional composition to a subject, the method comprising:
exposing a nutritional composition comprising triglycerides and/or esters to an immobilized lipase to form a hydrolyzed nutritional composition;
separating the hydrolyzed nutritional composition from the immobilized lipase after the exposing step, wherein the hydrolyzed nutritional composition is ready for ingestion after the separating; and
delivering the hydrolyzed nutritional composition to the subject for ingestion after the separating,
wherein the method reduces a length of time the subject is on parenteral nutrition.
22 . The method of claim 21 , wherein the nutritional composition is exposed to the immobilized lipase for at least one minute, prior to delivering the hydrolyzed nutritional composition to the subject.
23 . The method of claim 21 , wherein the nutritional composition is exposed to the immobilized lipase for no more than thirty seconds, prior to delivering the hydrolyzed nutritional composition to the subject.
24 . The method of claim 21 , wherein the nutritional composition is exposed to the immobilized lipase for no more than one minute, prior to delivering the hydrolyzed nutritional composition to the subject.
25 . The method of claim 21 , wherein the nutritional composition is exposed to the immobilized lipase for no more than five minutes, prior to delivering the hydrolyzed nutritional composition to the subject.
26 . The method of claim 21 , wherein the nutritional composition is one of an infant formula, milk, or an enteral formula.
27 . The method of claim 21 , wherein the hydrolyzed nutritional composition is delivered to the subject for ingestion via a feeding tube.
28 . The method of claim 21 , wherein after the exposing step, the hydrolyzed nutritional composition comprises more free fatty acids than monoglycerides.
29 . The method of claim 21 , wherein the method further reduces gut atrophy.
30 . The method of claim 21 , wherein the subject is diagnosed with at least one of: Alzheimer's disease, bipolar disorder, depression, sepsis, acute respiratory stress, cancer, cardiovascular disease, stroke, Parkinson's disease, schizophrenia, diabetes, multiple sclerosis, malnutrition, impaired GI function, rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, short bowel syndrome, irritable bowel disorder, Systemic Inflammatory Response Syndrome, celiac disease, Crohn's disease, Cystic Fibrosis, Zollinger-Ellison syndrome, hypertriglyceridemia, neoplasms, hemochromatosis, primary sclerosing cholangitis, primary biliary cirrhosis, diarrhea, Shwachman's syndrome, trypsinogen deficiency, enterokinase deficiency, chylothorax, isolated deficiency of lipase, premature birth, pancreatic insufficiency, pancreatitis, malabsorption, compromised pancreatic output, a reduced ability to hydrolyze triglycerides or esters, or a reduced ability to absorb triglycerides or esters.
31 . A method of providing a nutritional composition to a subject, the method comprising:
exposing a nutritional composition comprising triglycerides and/or esters to an immobilized lipase to form a hydrolyzed nutritional composition;
separating the hydrolyzed nutritional composition from the immobilized lipase after the exposing step, wherein the hydrolyzed nutritional composition is ready for ingestion after the separating; and
delivering the hydrolyzed nutritional composition to the subject for ingestion after the separating step,
wherein the method reduces gut atrophy in the subject.
32 . The method of claim 31 , wherein the nutritional composition is one of an infant formula, milk, or an enteral formula.
33 . The method of claim 31 , wherein the hydrolyzed nutritional composition is delivered to the subject for ingestion via a feeding tube.
34 . The method of claim 31 , wherein after the exposing step, the hydrolyzed nutritional composition comprises more free fatty acids than monoglycerides.
35 . The method of claim 31 , wherein the method further reduces a length of time the subject is on total parenteral nutrition.
36 . The method of claim 31 , wherein the nutritional composition is exposed to the immobilized lipase for at least one minute, prior to delivering the hydrolyzed nutritional composition to the subject.
37 . The method of claim 31 , wherein the nutritional composition is exposed to the immobilized lipase for no more than thirty seconds, prior to delivering the hydrolyzed nutritional composition to the subject.
38 . The method of claim 31 , wherein the nutritional composition is exposed to the immobilized lipase for no more than five minutes, prior to delivering the hydrolyzed nutritional composition to the subject.
39 . The method of claim 31 , wherein the nutritional composition is exposed to the immobilized lipase for no more than sixty minutes, prior to delivering the hydrolyzed nutritional composition to the subject.
40 . The method of claim 31 , wherein the subject is diagnosed with at least one of: Alzheimer's disease, bipolar disorder, depression, sepsis, acute respiratory stress, cancer, cardiovascular disease, stroke, Parkinson's disease, schizophrenia, diabetes, multiple sclerosis, malnutrition, impaired GI function, rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, short bowel syndrome, irritable bowel disorder, Systemic Inflammatory Response Syndrome, celiac disease, Crohn's disease, Cystic Fibrosis, Zollinger-Ellison syndrome, hypertriglyceridemia, neoplasms, hemochromatosis, primary sclerosing cholangitis, primary biliary cirrhosis, diarrhea, Shwachman's syndrome, trypsinogen deficiency, enterokinase deficiency, chylothorax, isolated deficiency of lipase, premature birth, pancreatic insufficiency, pancreatitis, malabsorption, compromised pancreatic output, a reduced ability to hydrolyze triglycerides or esters, or a reduced ability to absorb triglycerides or esters.